Generic Name:
pegvaliase
Project Status:
Active
Therapeutic Area:
Phenylketonuria
Manufacturer:
BioMarin Pharmaceutical Inc.
Brand Name:
Palynziq
Project Line:
Reimbursement Review
Project Number:
SR0712-000
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.